New Head of sanofi-aventis Human Resources Department
Dr. Heinz-Werner Meier appointed Senior Vice President, Human Resources to succeed Jean-Claude Armbruster
Ämnen: Haelso-sjukvaard
-
-
Sanofi-aventis withdraws European application for marketing authorization for dronedarone (MULTAQ) in the treatment of Atrial Fibrillation/Atrial Flutter
Sanofi-aventis announced today that it has taken the decision to withdraw the European application for Marketing Authorisation of dronedarone (MULTAQ), 400 mg film-coated tablets intended for use in the treatment of Atrial Fibrillation / Atrial Flutter.
-
EUROPEAN COMMISSION EXPANDS INDICATION FOR PLAVIX OFFERING NEW OPTION FOR PATIENTS WITH MOST SEVERE TYPE OF HEART ATTACK
- PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS)-
-
New clinical data show enoxaparin significantly reduces the risk of repeat heart attacks and stroke in patients undergoing percutaneous coronary intervention (PCI)
Results of the PCI-ExTRACT-TIMI 25 study announced today at the World Congress of Cardiology-European Society of Cardiology 2006 in Barcelona.
-
Richard Jeppsson ny public affairs director på sanofi-aventis
För att driva sakfrågor och ytterligare förstärka sanofi-aventis roll inrättas en ny avdelning för Public Affairs.
-
OSTEOPOROSIS TREATMENT NOW APPROVED IN EUROPE & US FOR MEN
Male osteoporosis: Neglected and Under Treated Paris, August 17, 2006 The US Food and Drug Administration (FDA) this week approved Actonel® 35mg (risedronate sodium tablets) for treatment to increase bone mass in men with osteoporosis
-
FDA APPROVES NEW INDICATION FOR PLAVIX (clopidogrel bisulfate) OFFERING NEW OPTION FOR PATIENTS
Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved the supplemental new drug application for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction.
-
First half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis1 Adjusted EPS1 growth of 32.9%, or 16.1% excluding selected items3
The consolidated income statement for the first half of 2006 is provided in the appendices. 2006 first-half consolidated net income after minority interests was 2,381 million, compared with 1,087 million for the first half of 2005, after the impact of the accounting treatment of acquisitions (primarily the acquisition of Aventis) and restructuring costs (1,583 million after tax in 2006 and 1,8
-
Results 1st half 2006
Läs Sanofi-Aventis resultat för första hälften av 2006 i bifogade dokument.
-
Sanofi-aventis responds to the emergency request for humanitarian aid to Lebanon
Sanofi-aventis responded immediately on Tuesday evening to the call for medical assistance launched by the French Foreign Ministry, to offer support to Lebanon's health authorities and express solidarity with the people of Lebanon.
-
Ny insulinpenna till måltidsinsulinet Apidra
Måltidsinsulinet Apidra lanseras nu i en engångspenna. Pennan heter OptiSet och är förfylld med Apidra vilket underlättar för patienterna.
-
Läkemedlet Acomplia® godkänt för försäljning i EU
EU-kommissionen offentliggjorde igår att läkemedlet Acomplia® (rimonabant) godkänts för försäljning i samtliga EU-länder. Acomplia® är en ny och unik substans som påverkar ett flertal riskfaktorer för hjärtinfarkt och stroke. Sanofi-aventis räknar med att Acomplia® kommer att finnas tillgängligt på den svenska marknaden i början av 2007.
-
ACOMPLIA® (RIMONABANT) RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION
First-in-class CB1 blocker approved for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia
-
Lång- och korttidsverkande insulin i jämförande studie: Färre injektioner, färre känningar och stabilare blodsockernivåer med insulin glargin
Behandling med insulin glargin ger låga blodsockernivåer och färre insulinkänningar med en tredjedel så många injektioner som behandling med insulin lispro. Detta visar Apollo-studien som redovisades på den årliga diabeteskongressen, American Diabetes Associations, ADA, som hölls i Washington D.C. i veckan.
-
NEW STUDY SHOWS INSULIN GLARGINE (LANTUS®) AS EFFECTIVE AND BETTER TOLERATED THAN THE PRANDIAL INSULIN LISPRO IN INITIATING INSULIN THERAPY IN TYPE 2 DIABETES
Apollo study shows insulin glargine achieves HbA1c below 7% with less hypoglycemia, 3 times less insulin injections and less self-monitoring than the prandial analog lispro.
-
NEW STUDY SHOWS AN INNOVATIVE MEALTIME INSULIN DOSING ALGORITHM MAY PROVIDE A SAFE AND EFFECTIVE ALTERNATIVE TO CARBOHYDRATE COUNTING FOR PATIENTS WITH TYPE 2 DIABETES
Type 2 Diabetes Patients Using a New Insulin Dosing Strategy Achieved a Mean A1C of 6.6% after 24 Weeks of Combination Therapy with Rapid-Acting Apidra® (insulin glulisine [rDNA origin] injection) and 24-hour Lantus® (insulin glargine [rDNA origin] injection).
-
STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS
Paris, France, June 7, 2006 Sanofiaventis announced today key trial results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia, regarding the use of Taxotere® (docetaxel) regimens in the treatment of non small cell lung cancer (NSCLC), head and neck cancer and metastatic and adjuvant breast cancer.
-
STUDIES EVALUATING ELOXATIN®-BASED REGIMENS IN GASTROINTESTINAL CANCERS PRESENTED AT THE 42nd ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
Sanofiaventis announced today key results from three studies evaluating Eloxatin® (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, pancreatic and gastric cancers). These results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.
-
Results of a meta-analysis show benefits of Taxotere® (docetaxel) regimens in patients with advanced non-small cell lung cancer (NSCLC)
Sanofi-aventis announced today that a meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer showed that patients receiving Taxotere® (docetaxel) Injection Concentrate had demonstrated overall survival and less febrile neutropenia than those treated with vinca-alkaloid (vinorelbine or vindesine) regimens.
-
Sanofi-aventis stärker sin organisation
Sanofi-aventis befinner sig i en expansiv fas med förberedelser inför lansering av ny produkt och många spännande studier i pipeline. Detta resulterar i en omfattande rekrytering.
Visa mer
Loading...